KCF advised Genfit on the restructuring of its outstanding convertible bond
Januray 2021
KCF acted as Joint Advisor to Genfit on the partial buyback and renegotiation of the company’s EUR180m convertible bond.
Genfit is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases.